Skip to main content
Premium Trial:

Request an Annual Quote

BioCommerce Week s Index to the Diversified Molecular Biology Tools Companies: Nov 25, 2004

 

Bruker Insider Buy Bolsters 17-Percent Weekly Gain; Index Climbs

Bruker BioScience’s share price closed a shortened coverage period for the BioCommerce Week Index on Monday at $4.33, a 17-percent gain based largely on an insider purchase of 200,000 shares by CEO Frank Laukien last week.

Bruker’s gain offset share-price losses by seven of the 15 select molecular biology companies tracked in the index in the four-day period ending Monday. The usual five-day tracking period for the index was shortened due to early Thanksgiving holiday publishing deadlines.

Bio-Rad followed Bruker’s gain with a 5-percent improvement on the week, closing at $55.66, up from $53.68 last week as investors apparently responded to the as-yet unverified possibility of another US case of mad cow disease. (See story, page 1).

Other gainers on the week included Applied Biosystems, closing at $20.57, up 3 percent from last week’s $20.00 close; and Beckman Coulter, closing at $63.74, up 2 percent over last week’s $62.68. Sigma also closed up at $58.68, a 1-percent increase over last week’s $57.88, followed by Waters, closing at $46.41, up from $45.85 last week.

Agilent and BD each were up a fraction of a percent. Agilent closed at $23.08, up from $22.95. BD closed at $54.72, up from $54.53 last week.

PerkinElmer led the week’s losers with a 5 percent drop, closing Monday at $20.80, down from $21.80 last week. Stratagene dropped to $6.80 from last week’s $6.92, marking a third straight weekly loss for the La Jolla, Calif.-based reagent marketer. Invitrogen closed at $61.54, from from $61.88 last week.

Overall, the index closed at $33.92, up 1 percent over last week’s $33.57 close and marking a fourth consecutive week of gains.

For the week, the index outperformed all of the large indexes as the Nasdaq, S&P 500, and the Dow all fell a fraction of a percent. Meantime, the Amex Biotech index dropped just under 2 percent while the Amex Pharma Index dropped approximately 2.5 percent.

File Attachments
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.